Marco Iafolla

1.3k total citations
38 papers, 451 citations indexed

About

Marco Iafolla is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Marco Iafolla has authored 38 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Marco Iafolla's work include Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (13 papers) and Renal cell carcinoma treatment (9 papers). Marco Iafolla is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (13 papers) and Renal cell carcinoma treatment (9 papers). Marco Iafolla collaborates with scholars based in Canada, United States and Denmark. Marco Iafolla's co-authors include Rosalyn A. Juergens, David Allan, Jason Tay, David R. McMillen, Aaron R. Hansen, Shaan Dudani, Frede Donskov, Jeffrey Graham, Ulka N. Vaishampayan and Daniel Y.C. Heng and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Physical Chemistry B.

In The Last Decade

Marco Iafolla

37 papers receiving 444 citations

Peers

Countries citing papers authored by Marco Iafolla

Since Specialization

Citations

This map shows the geographic impact of Marco Iafolla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Iafolla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Iafolla more than expected).

Fields of papers citing papers by Marco Iafolla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Iafolla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Iafolla. The network helps show where Marco Iafolla may publish in the future.

Co-authorship network of co-authors of Marco Iafolla

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Iafolla. A scholar is included among the top collaborators of Marco Iafolla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Iafolla. Marco Iafolla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y 2025 ·Annals of Oncology ·Terence W. Friedlander, Peter H. O’Donnell, (unknown), Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Rana R. McKay, (unknown), Saby George, Jason R. Brown, Mehmet Asım Bilen, Delphine Borchiellini, Marco Iafolla, Abhishek Bavle, M. C. Mihm, Y. Zhu, Changting Meng, Jacob Rosenberg	0
2	Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), Shaan Dudani, Marco Iafolla, Kashif Irshad, (unknown), (unknown), (unknown), David Chun Cheong Tsui, Xin Wang, (unknown), Parneet Cheema, Brandon S. Sheffield	6
3	Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors 2024 ·Current Oncology ·Parneet Cheema, Marco Iafolla, Husam Abdel‐Qadir, Alice Bellini, (unknown), Natasha Chandok, Vikram Comondore, Morven Cunningham, Ilana Halperin, (unknown), (unknown), Saeed Darvish‐Kazem, Masud H. Khandaker, Abhijat Kitchlu, (unknown), Shane Shapera, (unknown), (unknown)	7
4	Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care 2022 ·Current Oncology ·Brandon S. Sheffield, (unknown), (unknown), (unknown), Marco Iafolla, (unknown), Shaan Dudani, Mary Anne Brett, (unknown), Brian Olsen, Parneet Cheema	31
5	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre 2022 ·Current Oncology ·Parneet Cheema, Marco Iafolla, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Shaan Dudani, (unknown), (unknown), Philip Kuruvilla, (unknown), Henry Jacob Conter	3
6	Changes in circulating tumor DNA (ctDNA) and outcomes in solid tumors treated with immune checkpoint inhibitors (ICIs). 2022 ·Journal of Clinical Oncology ·(unknown), Marco Iafolla, (unknown), (unknown), Abhenil Mittal, David W. Cescon, Eitan Amir	1
7	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy 2021 ·PLoS ONE ·Morven Cunningham, Marco Iafolla, Yada Kanjanapan, Orlando Cerocchi, Marcus O. Butler, Lillian L. Siu, Philippe L. Bédard, (unknown), Bettina E. Hansen, Anna Spreafico, Jordan J. Feld	25
8	Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts 2020 ·JNCI Cancer Spectrum ·Marco Iafolla, Sarah Picardo, Kyaw Aung, Aaron R. Hansen	2
9	Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody. 2020 ·Journal of Clinical Oncology ·Amita Patnaik, Anna Spreafico, Alison M. Paterson, (unknown), (unknown), (unknown), (unknown), (unknown), Muralidhar Beeram, Marco Iafolla, (unknown), Alison M. Schram	18
10	Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value 2019 ·Molecular Cancer Therapeutics ·(unknown), Marco Iafolla, (unknown), Antoninus Soosaipillai, Ioannis Prassas, Eleftherios P. Diamandis	10
11	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts 2019 ·PLoS ONE ·Marco Iafolla, Sarah Picardo, Kyaw Aung, Aaron R. Hansen	8
12	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors 2019 ·European Urology Oncology ·Jeffrey Graham, Amishi Y. Shah, J. Connor Wells, Rana R. McKay, Ulka N. Vaishampayan, Aaron R. Hansen, Frede Donskov, Georg A. Bjarnason, Benoit Beuselinck, Guillermo de Velasco, Marco Iafolla, Mei Sheng Duh, Lynn Huynh, (unknown), Giovanni Zanotti, Krishnan Ramaswamy, Toni K. Choueiri, Nizar M. Tannir, Daniel Y.C. Heng	30
13	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium 2019 ·European Urology ·Shaan Dudani, Jeffrey Graham, J. Connor Wells, Ziad Bakouny, Sumanta K. Pal, Nazlı Dizman, Frede Donskov, Camillo Porta, Guillermo de Velasco, Aaron R. Hansen, Marco Iafolla, Benoit Beuselinck, Ulka N. Vaishampayan, Lori Wood, Elizabeth Liow, Flora Yan, Takeshi Yuasa, Georg A. Bjarnason, Toni K. Choueiri, Daniel Y.C. Heng	66
14	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P). 2019 ·Journal of Clinical Oncology ·Marco Iafolla, Cindy Yang, Scott Dashner, Wei Xu, Aaron R. Hansen, Philippe L. Bédard, Stéphanie Lheureux, Anna Spreafico, Albiruni Ryan Abdul Razak, Hsin-Ta Wu, Svetlana Shchegrova, Zhihui Liu, Pamela S. Ohashi, Dax Torti, Maggie C. Louie, Himanshu Sethi, Alexey Aleshin, Lillian L. Siu, Scott V. Bratman, Trevor J. Pugh	7
15	The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years 2018 ·Transplantation ·Anthea Peters, (unknown), Carlos Cervera, (unknown), Sunita Ghosh, Raymond Lai, Marco Iafolla, Karen Doucette, Jutta K. Preiksaitis	52
16	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer 2017 ·Frontiers in Oncology ·Marco Iafolla, Rosalyn A. Juergens	23
17	Transplantation of Umbilical Cord Blood–Derived Cells for Novel Indications in Regenerative Therapy or Immune Modulation: A Scoping Review of Clinical Studies 2013 ·Biology of Blood and Marrow Transplantation ·Marco Iafolla, Jason Tay, David Allan	32
18	Curricular mapping: an anti-stress tool for new medical students 2012 ·Education in Medicine Journal ·(unknown), Marco Iafolla, Stephanie Sutherland, Alireza Jalali	1
19	Dark proteins: Effect of inclusion body formation on quantification of protein expression 2008 ·Proteins Structure Function and Bioinformatics ·Marco Iafolla, (unknown), (unknown), (unknown), (unknown), David R. McMillen	26
20	Simplification of Stochastic Chemical Reaction Models with Fast and Slow Dynamics 2007 ·Journal of Biological Physics ·Guang Qiang Dong, (unknown), Marco Iafolla, David R. McMillen	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact